<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39339968</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1492</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091492</ELocationID><Abstract><AbstractText>Over the past three years, new SARS-CoV-2 variants have continuously emerged, evolving to a point where an immune response against the original vaccine no longer provided optimal protection against these new strains. During this time, high-throughput neutralization assays based on pseudoviruses have become a valuable tool for assessing the efficacy of new vaccines, screening updated vaccine candidates against emerging variants, and testing the efficacy of new therapeutics such as monoclonal antibodies. Lentiviral vectors derived from HIV-1 are popular for developing pseudo and chimeric viruses due to their ease of use, stability, and long-term transgene expression. However, the HIV-based platform has lower transduction rates for pseudotyping coronavirus spike proteins than other pseudovirus platforms, necessitating more optimized methods. As the SARS-CoV-2 virus evolved, we produced over 18 variants of the spike protein for pseudotyping with an HIV-based vector, optimizing experimental parameters for their production and transduction. In this article, we present key parameters that were assessed to improve such technology, including (a) the timing and method of collection of pseudovirus supernatant; (b) the timing of host cell transduction; (c) cell culture media replenishment after pseudovirus adsorption; and (d) the centrifugation (spinoculation) parameters of the host cell+ pseudovirus mix, towards improved transduction. Additionally, we found that, for some pseudoviruses, the addition of a cationic polymer (polybrene) to the culture medium improved the transduction process. These findings were applicable across variant spike pseudoviruses that include not only SARS-CoV-2 variants, but also SARS, MERS, Alpha Coronavirus (NL-63), and bat-like coronaviruses. In summary, we present improvements in transduction efficiency, which can broaden the dynamic range of the pseudovirus titration and neutralization assays.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thimmiraju</LastName><ForeName>Syamala Rani</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Texas Children's Hospital Center for Vaccine Development, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villar</LastName><ForeName>Maria Jose</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Texas Children's Hospital Center for Vaccine Development, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimata</LastName><ForeName>Jason T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0002-0504-0090</Identifier><AffiliationInfo><Affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strych</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-9455-7683</Identifier><AffiliationInfo><Affiliation>Texas Children's Hospital Center for Vaccine Development, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottazzi</LastName><ForeName>Maria Elena</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-8429-0476</Identifier><AffiliationInfo><Affiliation>Texas Children's Hospital Center for Vaccine Development, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotez</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Texas Children's Hospital Center for Vaccine Development, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollet</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1420-4015</Identifier><AffiliationInfo><Affiliation>Texas Children's Hospital Center for Vaccine Development, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1P30CA125123-23A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CPRIT-RP180672</GrantID><Agency>CPRIT</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014161" MajorTopicYN="Y">Transduction, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089942" MajorTopicYN="N">Viral Pseudotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronaviruses</Keyword><Keyword MajorTopicYN="N">lentiviral pseudoviruses</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">polybrene</Keyword><Keyword MajorTopicYN="N">spinoculation</Keyword><Keyword MajorTopicYN="N">transduction efficiency</Keyword></KeywordList><CoiStatement>Several of the authors are co-inventors of a COVID-19 recombinant protein vaccine technology held by Baylor College of Medicine (BCM). BCM has licensed this technology non-exclusively to multiple companies dedicated to improving vaccine access in low- and middle-income countries, with no patent restrictions. The authors themselves are not directly involved in the licensing negotiations led by BCM. None of the authors have additional competing financial or non-financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339968</ArticleId><ArticleId IdType="pmc">PMC11437443</ArticleId><ArticleId IdType="doi">10.3390/v16091492</ArticleId><ArticleId IdType="pii">v16091492</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaufer A.M., Theis T., Lau K.A., Gray J.L., Rawlinson W.D. Laboratory Biosafety Measures Involving SARS-CoV-2 and the Classification as a Risk Group 3 Biological Agent. Pathology. 2020;52:790–795. doi: 10.1016/j.pathol.2020.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pathol.2020.09.006</ArticleId><ArticleId IdType="pmc">PMC7524674</ArticleId><ArticleId IdType="pubmed">33070960</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolah A.M.K., Sohrab S.S., Tolah K.M.K., Hassan A.M., El-Kafrawy S.A., Azhar E.I. Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay. Diagnostics. 2021;11:994. doi: 10.3390/diagnostics11060994.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11060994</ArticleId><ArticleId IdType="pmc">PMC8226551</ArticleId><ArticleId IdType="pubmed">34070824</ArticleId></ArticleIdList></Reference><Reference><Citation>D’apice L., Trovato M., Gramigna G., Colavita F., Francalancia M., Matusali G., Meschi S., Lapa D., Bettini A., Mizzoni K., et al. Comparative Analysis of the Neutralizing Activity against SARS-CoV-2 Wuhan-Hu-1 Strain and Variants of Concern: Performance Evaluation of a Pseudovirus-Based Neutralization Assay. Front. Immunol. 2022;13:981693. doi: 10.3389/fimmu.2022.981693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.981693</ArticleId><ArticleId IdType="pmc">PMC9549111</ArticleId><ArticleId IdType="pubmed">36225911</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Phillips D.J., White T., Sayal H., Aley P.K., Bibi S., Dold C., Fuskova M., Gilbert S.C., Hirsch I., et al. Correlates of Protection against Symptomatic and Asymptomatic SARS-CoV-2 Infection. Nat. Med. 2021;27:2032–2040. doi: 10.1038/s41591-021-01540-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldblatt D., Alter G., Crotty S., Plotkin S.A. Correlates of Protection against SARS-CoV-2 Infection and COVID-19 Disease. Immunol. Rev. 2022;310:6–26. doi: 10.1111/imr.13091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13091</ArticleId><ArticleId IdType="pmc">PMC9348242</ArticleId><ArticleId IdType="pubmed">35661178</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., Astudillo M.G., Yang D., Miller T.E., Feldman J., Hauser B.M., Caradonna T.M., Clayton K.L., Nitido A.D., et al. COVID-19-Neutralizing Antibodies Predict Disease Severity and Survival. Cell. 2021;184:476–488.e11. doi: 10.1016/j.cell.2020.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.015</ArticleId><ArticleId IdType="pmc">PMC7837114</ArticleId><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–280.e278. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L., Gao G.F. Viral Targets for Vaccines against COVID-19. Nat. Rev. Immunol. 2021;21:73–82. doi: 10.1038/s41577-020-00480-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00480-0</ArticleId><ArticleId IdType="pmc">PMC7747004</ArticleId><ArticleId IdType="pubmed">33340022</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Iketani S., Guo Y., Chan J.F.-W., Wang M., Liu L., Luo Y., Chu H., Huang Y., Nair M.S., et al. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. Nature. 2022;602:676–681. doi: 10.1038/s41586-021-04388-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04388-0</ArticleId><ArticleId IdType="pubmed">35016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou F., Li M., Pang Z., Jiang L., Guan L., Tian L., Hu J., Fan J., Fan H. Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. Front. Immunol. 2021;12:744242. doi: 10.3389/fimmu.2021.744242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.744242</ArticleId><ArticleId IdType="pmc">PMC8602852</ArticleId><ArticleId IdType="pubmed">34804024</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H.O., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J., et al. A Serological Assay to Detect SARS-CoV-2 Seroconversion in Humans. Nat. Med. 2020;26:1033–1036. doi: 10.1038/s41591-020-0913-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0913-5</ArticleId><ArticleId IdType="pmc">PMC8183627</ArticleId><ArticleId IdType="pubmed">32398876</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K.-T., Han Y.-J., Wu G.-H., Huang K.-Y.A., Huang P.-N. Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. Viruses. 2022;14:1560. doi: 10.3390/v14071560.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14071560</ArticleId><ArticleId IdType="pmc">PMC9322699</ArticleId><ArticleId IdType="pubmed">35891540</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Liu L., Kou G., Zheng Y., Ding Y., Ni W., Wang Q., Tan L., Wu W., Tang S., et al. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. J. Clin. Microbiol. 2020;58:e00461-20. doi: 10.1128/JCM.00461-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00461-20</ArticleId><ArticleId IdType="pmc">PMC7269413</ArticleId><ArticleId IdType="pubmed">32229605</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantoni D., Mayora-Neto M., Temperton N. The Role of Pseudotype Neutralization Assays in Understanding SARS CoV-2. Oxf. Open Immunol. 2021;2:iqab005. doi: 10.1093/oxfimm/iqab005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqab005</ArticleId><ArticleId IdType="pmc">PMC7928640</ArticleId><ArticleId IdType="pubmed">33738456</ArticleId></ArticleIdList></Reference><Reference><Citation>Chmielewska A.M., Czarnota A., Bieńkowska-Szewczyk K., Grzyb K. Immune Response against SARS-CoV-2 Variants: The Role of Neutralization Assays. NPJ Vaccines. 2021;6:142. doi: 10.1038/s41541-021-00404-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00404-6</ArticleId><ArticleId IdType="pmc">PMC8630184</ArticleId><ArticleId IdType="pubmed">34845231</ArticleId></ArticleIdList></Reference><Reference><Citation>Thimmiraju S.R., Kimata J.T., Pollet J. Pseudoviruses, a Safer Toolbox for Vaccine Development against Enveloped Viruses. Expert Rev. Vaccines. 2024;23:174–185. doi: 10.1080/14760584.2023.2299380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2299380</ArticleId><ArticleId IdType="pubmed">38164690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright E., Temperton N.J., Marston D.A., McElhinney L.M., Fooks A.R., Weiss R.A. Investigating Antibody Neutralization of Lyssaviruses Using Lentiviral Pseudotypes: A Cross-Species Comparison. J. Gen. Virol. 2008;89:2204–2213. doi: 10.1099/vir.0.2008/000349-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/000349-0</ArticleId><ArticleId IdType="pmc">PMC2886951</ArticleId><ArticleId IdType="pubmed">18753230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X., Angelo L.S., Nicholson E.G., Iwuchukwu O.P., Cabral de Rezende W., Rajan A., Aideyan L.O., McBride T.J., Bond N., Santarcangelo P., et al. Serum IgG Anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated with IgA and Functional Antibody Levels in Adults Infected with SARS-CoV-2. Front. Immunol. 2021;12:693462. doi: 10.3389/fimmu.2021.693462.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.693462</ArticleId><ArticleId IdType="pmc">PMC8531527</ArticleId><ArticleId IdType="pubmed">34691016</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollet J., Strych U., Chen W.-H., Versteeg L., Keegan B., Zhan B., Wei J., Liu Z., Lee J., Kundu R., et al. Receptor-Binding Domain Recombinant Protein on Alum-CpG Induces Broad Protection against SARS-CoV-2 Variants of Concern. Vaccine. 2022;40:3655–3663. doi: 10.1016/j.vaccine.2022.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.007</ArticleId><ArticleId IdType="pmc">PMC9080055</ArticleId><ArticleId IdType="pubmed">35568591</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J., Li Q., Wu J., Zhao C., Hao H., Liu H., Zhang L., Nie L., Qin H., Wang M., et al. Quantification of SARS-CoV-2 Neutralizing Antibody by a Pseudotyped Virus-Based Assay. Nat. Protoc. 2020;15:3699–3715. doi: 10.1038/s41596-020-0394-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-0394-5</ArticleId><ArticleId IdType="pubmed">32978602</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford K.H.D., Eguia R., Dingens A.S., Loes A.N., Malone K.D., Wolf C.R., Chu H.Y., Tortorici M.A., Veesler D., Murphy M., et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses. 2020;12:513. doi: 10.3390/v12050513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12050513</ArticleId><ArticleId IdType="pmc">PMC7291041</ArticleId><ArticleId IdType="pubmed">32384820</ArticleId></ArticleIdList></Reference><Reference><Citation>Neerukonda S.N., Vassell R., Herrup R., Liu S., Wang T., Takeda K., Yang Y., Lin T.-L., Wang W., Weiss C.D. Establishment of a Well-Characterized SARS-CoV-2 Lentiviral Pseudovirus Neutralization Assay Using 293T Cells with Stable Expression of ACE2 and TMPRSS2. PLoS ONE. 2021;16:e0248348. doi: 10.1371/journal.pone.0248348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0248348</ArticleId><ArticleId IdType="pmc">PMC7946320</ArticleId><ArticleId IdType="pubmed">33690649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Wang J., Li Q., Hu H., Lu J., Chen Z. Advances in Neutralization Assays for SARS-CoV-2. Scand. J. Immunol. 2021;94:e13088. doi: 10.1111/sji.13088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.13088</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollet J., Chen W.-H., Versteeg L., Keegan B., Zhan B., Wei J., Liu Z., Lee J., Kundu R., Adhikari R., et al. SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-Cell Immunity in Mice. Hum. Vaccines Immunother. 2021;17:2356–2366. doi: 10.1080/21645515.2021.1901545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.1901545</ArticleId><ArticleId IdType="pmc">PMC8054496</ArticleId><ArticleId IdType="pubmed">33847226</ArticleId></ArticleIdList></Reference><Reference><Citation>Thimmiraju S.R., Adhikari R., Redd J.R., Villar M.J., Lee J., Liu Z., Chen Y.-L., Sharma S., Kaur A., Uzcategui N.L., et al. A Trivalent Protein-Based Pan-Betacoronavirus Vaccine Elicits Cross-Neutralizing Antibodies against a Panel of Coronavirus Pseudoviruses. NPJ Vaccines. 2024;9:132. doi: 10.1038/s41541-024-00924-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00924-x</ArticleId><ArticleId IdType="pmc">PMC11271464</ArticleId><ArticleId IdType="pubmed">39034332</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A., Li F. Structural Basis of Receptor Recognition by SARS-CoV-2. Nature. 2020;581:221–224. doi: 10.1038/s41586-020-2179-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2179-y</ArticleId><ArticleId IdType="pmc">PMC7328981</ArticleId><ArticleId IdType="pubmed">32225175</ArticleId></ArticleIdList></Reference><Reference><Citation>Thimmiraju S.R., Adhikari R., Villar M.J., Lee J., Liu Z., Kundu R., Chen Y.-L., Sharma S., Ghei K., Keegan B., et al. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2. Vaccines. 2023;11:1557. doi: 10.3390/vaccines11101557.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11101557</ArticleId><ArticleId IdType="pmc">PMC10610638</ArticleId><ArticleId IdType="pubmed">37896960</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers T.F., Zhao F., Huang D., Beutler N., Burns A., He W.-T., Limbo O., Smith C., Song G., Woehl J., et al. Isolation of Potent SARS-CoV-2 Neutralizing Antibodies and Protection from Disease in a Small Animal Model. Science. 2020;369:956–963. doi: 10.1126/science.abc7520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc7520</ArticleId><ArticleId IdType="pmc">PMC7299280</ArticleId><ArticleId IdType="pubmed">32540903</ArticleId></ArticleIdList></Reference><Reference><Citation>Dacon C., Tucker C., Peng L., Lee C.-C.D., Lin T.-H., Yuan M., Cong Y., Wang L., Purser L., Williams J.K., et al. Broadly Neutralizing Antibodies Target the Coronavirus Fusion Peptide. Science. 2022;377:728–735. doi: 10.1126/science.abq3773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq3773</ArticleId><ArticleId IdType="pmc">PMC9348754</ArticleId><ArticleId IdType="pubmed">35857439</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., St Denis K., Nitido A.D., Garcia Z.H., Hauser B.M., Feldman J., Pavlovic M.N., Gregory D.J., Poznansky M.C., et al. Multiple SARS-CoV-2 Variants Escape Neutralization by Vaccine-Induced Humoral Immunity. Cell. 2021;184:2372–2383.e9. doi: 10.1016/j.cell.2021.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC7953441</ArticleId><ArticleId IdType="pubmed">33743213</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajabzadeh A., Hamidieh A.A., Rahbarizadeh F. Spinoculation and Retronectin Highly Enhance the Gene Transduction Efficiency of Mucin-1-Specific Chimeric Antigen Receptor (CAR) in Human Primary T Cells. BMC Mol. Cell Biol. 2021;22:57. doi: 10.1186/s12860-021-00397-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12860-021-00397-z</ArticleId><ArticleId IdType="pmc">PMC8609792</ArticleId><ArticleId IdType="pubmed">34814824</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreu S., Ripa I., Bello-Morales R., López-Guerrero J.A. Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In Vitro. Viruses. 2023;15:972. doi: 10.3390/v15040972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040972</ArticleId><ArticleId IdType="pmc">PMC10142420</ArticleId><ArticleId IdType="pubmed">37112952</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Q., Li L., Wu J., Tian M., Fu Y. Application of Pseudovirus System in the Development of Vaccine, Antiviral-Drugs, and Neutralizing Antibodies. Microbiol. Res. 2022;258:126993. doi: 10.1016/j.micres.2022.126993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micres.2022.126993</ArticleId><ArticleId IdType="pmc">PMC8848573</ArticleId><ArticleId IdType="pubmed">35240544</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Doherty U., Swiggard W.J., Malim M.H. Human Immunodeficiency Virus Type 1 Spinoculation Enhances Infection through Virus Binding. J. Virol. 2000;74:10074–10080. doi: 10.1128/jvi.74.21.10074-10080.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.74.21.10074-10080.2000</ArticleId><ArticleId IdType="pmc">PMC102046</ArticleId><ArticleId IdType="pubmed">11024136</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren W., Qu X., Li W., Han Z., Yu M., Zhou P., Zhang S.-Y., Wang L.-F., Deng H., Shi Z. Difference in Receptor Usage between Severe Acute Respiratory Syndrome (SARS) Coronavirus and SARS-like Coronavirus of Bat Origin. J. Virol. 2008;82:1899–1907. doi: 10.1128/JVI.01085-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01085-07</ArticleId><ArticleId IdType="pmc">PMC2258702</ArticleId><ArticleId IdType="pubmed">18077725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng K.W., Faulkner N., Cornish G.H., Rosa A., Harvey R., Hussain S., Ulferts R., Earl C., Wrobel A.G., Benton D.J., et al. Preexisting and de Novo Humoral Immunity to SARS-CoV-2 in Humans. Science. 2020;370:1339–1343. doi: 10.1126/science.abe1107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe1107</ArticleId><ArticleId IdType="pmc">PMC7857411</ArticleId><ArticleId IdType="pubmed">33159009</ArticleId></ArticleIdList></Reference><Reference><Citation>Calado M., Matoso P., Santos-Costa Q., Espirito-Santo M., Machado J., Rosado L., Antunes F., Mansinho K., Lopes M.M., Maltez F., et al. Coreceptor Usage by HIV-1 and HIV-2 Primary Isolates: The Relevance of CCR8 Chemokine Receptor as an Alternative Coreceptor. Virology. 2010;408:174–182. doi: 10.1016/j.virol.2010.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2010.09.020</ArticleId><ArticleId IdType="pubmed">20947116</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M., Zhang X.-E. Construction and Applications of SARS-CoV-2 Pseudoviruses: A Mini Review. Int. J. Biol. Sci. 2021;17:1574–1580. doi: 10.7150/ijbs.59184.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.59184</ArticleId><ArticleId IdType="pmc">PMC8071765</ArticleId><ArticleId IdType="pubmed">33907521</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>